China says domestic drugs make up 80% of approved innovative medicines in first three quarters

The 80% domestic share is a signal about the maturity of China's innovative-drug pipeline rather than a one-quarter novelty, with the named research areas — oncology, psychiatry, anti-infectives, gout and rare disease — suggesting breadth beyond a single hot therapeutic category. For global pharma and biotech watchers, this points to a domestic industry increasingly able to supply its own innovative output, a shift with implications for licensing, partnership and competitive dynamics. Whether the domestic share holds as approval volumes move, and whether these breakthroughs translate into commercial or cross-border traction, is the open question.